Novartis reports Menveo data

Novartis (NYSE:NVS; SWX:NOVN) reported data on one of three co-primary endpoints in a U.S. Phase III meningococcal meningitis trial comparing single injections of Menveo with Menactra in about 3,500 volunteers aged 11-55. Menveo met the co-primary endpoint of non-inferiority to Menactra in 2,170 adolescents aged 11-18. The other two co-primary endpoints are non-inferiority vs. Menactra in volunteers aged 19-55 and lot consistency. sanofi-aventis (Euronext:SAN; NYSE:SNY) markets Menactra. Data were presented at the Pediatric Academic Societies meeting in Honolulu. ...